Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma

CONCLUSION: Our study showed a decrease in PD-L1 expression and disconnected molecular features during breast cancer progression. Repeating PD-L1 IHC testing could be considered in some specific metastatic sites if primary tumors were negative. Further studies are needed to identify other predictive factors for immune checkpoint inhibitor (ICI) therapy in patients with breast carcinoma.PMID:38492995 | DOI:10.1016/j.clbc.2024.02.010

Source: Clinical Genitourinary Cancer - March 16, 2024 Category: Cancer & Oncology Authors: Xiao Huang Sarah A Anderson Gene P Siegal Shi Wei Shanrun Liu Jingyun Yang Puentes Roisin J Taylor Pickens Lei Huo Aysegul A Sahin Carlos Prieto Granada Shuojun Chen Source Type: research